Droxidopa is commonly used clinically in the form of capsules, which works to promote the release of norepinephrine, improve blood circulation to the brain, and acts to improve conditions such as rigid gait and upright hypotension. Droxidopa capsule is a non-pharmacologically active norepinephrine precursor drug, which can be converted to norepinephrine in the body to promote the release of norepinephrine from the nerve endings and improve the symptoms caused by norepinephrine deficiency. The drug also significantly improves upright hypotension, as well as improves conditions triggered by loss of blood flow. Droxidopa Capsules are mainly used clinically to improve upright dizziness and gait stiffness caused by Parkinson’s disease, to improve weakness or dizziness caused by upright hypotension in hemodialysis patients, as well as to improve upright dizziness and fainting, upright hypotension caused by Shy-Drager syndrome or familial amyloid polyneuropathy. It should be noted that the drug is contraindicated in people who are allergic to any of the components of the drug, patients with angle-closure glaucoma, inhalation of halogen-containing anesthetics, pregnant women, those preparing for pregnancy, hemodialysis patients with severe extravasation injury, cocaine abusers, ventricular tachycardia is avoided non-essential. Some patients using Droxidopa Capsules may experience hallucinations, nausea, headache, headache, feeling of heaviness, elevated blood pressure and other adverse reactions, and in severe cases, nerve blocker malignant syndrome, such as hyperthermia, thought disorder, muscle stiffness, etc., and should be immediately sought medical attention. Patients should use Droxidopa Capsules in accordance with medical advice and avoid blindly using the drug on their own, so as not to induce side effects, or affect the condition.